Newsfile Corp
01 Sept 2026, 13:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA stated that the benefit-risk assessment for Capricor's lead product candidate, Deramiocel, appears unfavorable due to a lack of evidence of effectiveness. — A negative benefit-risk assessment from the FDA for a lead product candidate is often a precursor to drug rejection, fundamentally impairing the company's valuation.
-1.00The FDA rejected Capricor's statistical analysis plan (SAP) changes as not scientifically justified, labeling the resulting analyses as 'post-hoc and exploratory'. — Failure to agree on a statistical plan and the subsequent labeling of data as exploratory severely undermines the credibility of clinical trial results.
-0.80Berger Montague has filed a class action lawsuit against Capricor Therapeutics on behalf of investors who acquired securities between December 17, 2025, and July 26, 2026. — Class action lawsuits create additional legal liabilities and financial drains on a company, though they are often secondary to the underlying regulatory failure.
-0.40Continue reading
6 related stories
Search tags
Which stocks this story touches
The company faces a class action lawsuit following a 64% stock price drop and unfavorable FDA feedback on its lead product candidate.
The company is mentioned in the context of a class action lawsuit and deadline.
The company is the subject of a securities fraud class action notice.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
6h ago
